Synergene scientists follow thrombophilia course

Three scientists from Synergene Technologies recently attended a course in genetic and acquired thrombophilia held in Limassol, Cyprus between November 29 and December 2.

The course was co-sponsored by the European Genetics Foundation, a non-profit institution dedicated to the training of young geneticists and the promotion of the public understanding of genetics.

Thrombophilia is the tendency for abnormal blood clotting in the veins. Acquired thrombophilia is the tendency to clot that develops in adulthood or older age and which is not inherited.

The course covered various aspects of the disease including ways of detection, management and prevention in the case of the acquired disease.

The laboratory at Synergene offers a wide range of molecular diagnostic testing services including a thrombophilia panel which includes the following thrombosis risk factor mutations:

The Factor V Leiden mutation, Prothrombin (Factor II) mutation and the MTHFR variant.

The training received by the scientists is in line with the company's policy of continuously updating its technical expertise through internal and external training programmes.

The thrombophilia panel also involves testing for Deep Vein Thrombosis (DVT), which is a serious condition where blood clots develop in the deep veins of the legs. This disease may be associated with any form of long distance travel whether by air, car, coach or train. In particular. long-haul air travel (flights lasting longer than five hours) where passengers remain immobile in the seated position for long periods of time, may be associated with an increased risk.

For further information about this or other tests contact Synergene's scientific division on info@synergene.net.